Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation

Christopher J. Tape(Institute of Cancer Research), Stephanie Ling(Institute of Cancer Research), Maria Dimitriadi(Institute of Cancer Research), Kelly McMahon(University of Manchester), Jonathan D. Worboys(Institute of Cancer Research), Hui Sun Leong(University of Manchester), Ida C. Norrie(Institute of Cancer Research), Crispin Miller(University of Manchester), George Poulogiannis(Institute of Cancer Research), Douglas A. Lauffenburger(Massachusetts Institute of Technology), Claus Jørgensen(Institute of Cancer Research)
Cell
April 14, 2016
Cited by 379Open Access
Full Text

Abstract

Oncogenic mutations regulate signaling within both tumor cells and adjacent stromal cells. Here, we show that oncogenic KRAS (KRAS(G12D)) also regulates tumor cell signaling via stromal cells. By combining cell-specific proteome labeling with multivariate phosphoproteomics, we analyzed heterocellular KRAS(G12D) signaling in pancreatic ductal adenocarcinoma (PDA) cells. Tumor cell KRAS(G12D) engages heterotypic fibroblasts, which subsequently instigate reciprocal signaling in the tumor cells. Reciprocal signaling employs additional kinases and doubles the number of regulated signaling nodes from cell-autonomous KRAS(G12D). Consequently, reciprocal KRAS(G12D) produces a tumor cell phosphoproteome and total proteome that is distinct from cell-autonomous KRAS(G12D) alone. Reciprocal signaling regulates tumor cell proliferation and apoptosis and increases mitochondrial capacity via an IGF1R/AXL-AKT axis. These results demonstrate that oncogene signaling should be viewed as a heterocellular process and that our existing cell-autonomous perspective underrepresents the extent of oncogene signaling in cancer. VIDEO ABSTRACT.


Related Papers

No related papers found

Powered by citation graph analysis